Our top pick for
Inhibrx, Inc is a biotechnology business based in the US. Inhibrx shares (INBX) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibrx employs 75 staff and has a trailing 12-month revenue of around USD$10.4 million.
|Latest market close||USD$34.23|
|52-week range||USD$15.2 - USD$36.97|
|50-day moving average||USD$22.2465|
|200-day moving average||USD$19.9282|
|Wall St. target price||USD$30.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-0.84%|
|1 month (2020-12-17)||-31.54%|
|3 months (2020-10-16)||95.15%|
|6 months (2020-07-13)||N/A|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Revenue TTM||USD$10.4 million|
|Gross profit TTM||USD$-34,696,000|
|Return on assets TTM||-47.07%|
|Return on equity TTM||-259.35%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 265,399 Inhibrx shares held short by investors – that's known as Inhibrx's "short interest". This figure is 22.1% up from 217,327 last month.
There are a few different ways that this level of interest in shorting Inhibrx shares can be evaluated.
Inhibrx's "short interest ratio" (SIR) is the quantity of Inhibrx shares currently shorted divided by the average quantity of Inhibrx shares traded daily (recently around 57947.379912664). Inhibrx's SIR currently stands at 4.58. In other words for every 100,000 Inhibrx shares traded daily on the market, roughly 4580 shares are currently held short.
However Inhibrx's short interest can also be evaluated against the total number of Inhibrx shares, or, against the total number of tradable Inhibrx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inhibrx's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inhibrx shares in existence, roughly 10 shares are currently held short) or 0.0113% of the tradable shares (for every 100,000 tradable Inhibrx shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inhibrx.
Find out more about how you can short Inhibrx stock.
We're not expecting Inhibrx to pay a dividend over the next 12 months.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.